title: Splenic immune cells in experimental neonatal hypoxia-ischemia.
abstract: Neuroimmune processes contribute to hypoxic-ischemic damage in the immature brain and may play a role in the progression of particular variants of neonatal encephalopathy. The present study was designed to elucidate molecular mediators of interactions between astrocytes, neurons and infiltrating peripheral immune cells after experimental neonatal hypoxia-ischemia (HI). Splenectomy was performed on postnatal day-7 Sprague-Dawley rats 3 days prior to HI surgery; in which the right common carotid artery was permanently ligated followed by 2 hours of hypoxia (8% O2). Quantitative analysis showed that natural killer (NK) and T cell expression was reduced in spleen but increased in the brain following HI. Elevations in cyclooxygenase-2 (COX-2) expression after HI by immune cells promoted interleukin-15 expression in astrocytes and infiltration of inflammatory cells to site of injury; additionally, down-regulated the pro-survival protein, phosphoinositide-3-kinase, resulting in caspase-3 mediated neuronal death. The removal of the largest pool of peripheral immune cells in the body by splenectomy, COX-2 inhibitors, as well as rendering NK cells inactive by CD161 knockdown, significantly ameliorated cerebral infarct volume at 72 hours, diminished body weight loss and brain and systemic organ atrophy, and reduced neurobehavioral deficits at 3 weeks. Herein we demonstrate with the use of surgical approach (splenectomy), with pharmacological loss-gain function approach using COX-2 inhibitors/agonists, as well as with NK cell-type specific siRNA that after neonatal HI, the infiltrating peripheral immune cells may modulate downstream targets of cell death and neuroinflammation by COX-2 regulated signals.
authors.affiliation: Department of Human Anatomy and Pathology, Loma Linda University, Loma Linda, California, USA.
authors.forename: Nancy
authors.initials: N
authors.lastname: Fathali
authors.forename: Robert P
authors.initials: RP
authors.lastname: Ostrowski
authors.forename: Yu
authors.initials: Y
authors.lastname: Hasegawa
authors.forename: Tim
authors.initials: T
authors.lastname: Lekic
authors.forename: Jiping
authors.initials: J
authors.lastname: Tang
authors.forename: John H
authors.initials: JH
authors.lastname: Zhang
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D015153:Blotting, Western; D051546:Cyclooxygenase 2 / Q000276:immunology* / Q000378:metabolism; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology; D004195:Disease Models, Animal; D005455:Fluorescent Antibody Technique; D020925:Hypoxia-Ischemia, Brain / Q000276:immunology* / Q000378:metabolism / Q000473:pathology*; D007249:Inflammation / Q000276:immunology / Q000517:prevention & control; D007694:Killer Cells, Natural / Q000276:immunology; D015213:Neuroimmunomodulation / Q000276:immunology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013154:Spleen / Q000166:cytology / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D051546:Cyclooxygenase 2
keywords: NK cells; cyclooxygenase-2; hypoxia-ischemia; neonatal; neuroinflammation